Big Pharma leading in access-to-medicine strategies, shows data
The 2022 Access to Medicine Index shows all 20 pharma companies have an over-arching access to medicine strategy, benefitting low and middle-income countries.
List view / Grid view
The 2022 Access to Medicine Index shows all 20 pharma companies have an over-arching access to medicine strategy, benefitting low and middle-income countries.
Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
A University of Cambridge report assessing the preferred relationship type between pharma and contract research organisations (CROs), showed strategic partnerships will continue as the primary collaboration model.
Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.
The nearly $4bn ChemoCentryx acquisition will expand Amgen’s inflammation and nephrology portfolio and pipeline.
Through the acquisition of Global Blood Therapeutics, Pfizer aims to enhance its presence in rare haematology and particularly sickle cell disease (SCD).
Setting a new philanthropic benchmark, Pfizer is launching Accord for a Healthier World - an initiative aimed at closing the gap on inequalities with low-income countries.
According to a new report, the orphan drug market is growing more than twice as fast as the non-orphan market and, by 2026, orphan drug sales will account for 20 percent of all prescription drug sales.
After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer.
In 2021 we saw deals move away from the massive megamergers of 2019 to smaller collaboration and partnership agreements. In this article, European Pharmaceutical Review’s Hannah Balfour discusses the key deals of last year, whether the trend of high volume but small value will continue in 2022, and the motivations…
The investment will advance the development of a subcutaneous Sarclisa (isatuximab) formulation for multiple myeloma (MM) treatment.
The brain is protected by the blood-brain barrier, a multi-layered structure which helps to protect it from the invasion of pathogens or unwanted substances and limits drug transport into the brain via the bloodstream. Here, Dr Oliver Ernst and Dr Heiko Manninga from German biotech company NEUWAY Pharma share details of…